WuXi PharmaTech Inc. and Open Monoclonal Technology, Inc. (OMT) have entered a second agreement to expand WuXi’s use of OMT’s OmniRat and OmniMouse technologies aimed at strengthening the development and commercial opportunities for WuXi’s Asian regional and global clients.   WuXi has duplicated the OmniRat platform at its Shanghai facility, allowing it to generate antibodies for customers from its own labs. WuXi’s clients can now choose to develop and commercialize produ...